Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 15/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 15/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283987 | 0.85 | TLR7 (0.42) | TLR7EPHX2TLR8TLR2TLR1 | |
| SCHEMBL6287386 | 0.85 | TLR7 (0.40) | TLR7TLR8TLR2TLR1 | |
| SCHEMBL6782472 | 0.84 | FAAH (0.47) | TLR7TLR8 | |
| SCHEMBL6779395 | 0.82 | TLR7 (0.46) | TLR7TLR8 | |
| SCHEMBL6773388 | 0.82 | TLR7 (0.37) | TLR7TLR8 | |
| SCHEMBL6782361 | 0.81 | PTGER4 (0.42) | TLR7TLR8 | |
| SCHEMBL6772921 | 0.81 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL6094697 | 0.80 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL6096076 | 0.80 | TLR7 (0.45) | TLR7TLR8 | |
| SCHEMBL6772056 | 0.80 | KDM4E (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720334-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; 1-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)-3-PHENYLUREA. | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | claimed |
| US-6903113-B2 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040157879-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-6720334-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; 1-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)-3-PHENYLUREA. | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20030176458-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176458-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | TLR7 269/4885EPHX2 3159/4885TLR8 341/4885 |
| US-20040157879-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | TLR7 269/4885EPHX2 3159/4885TLR8 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.